(BPT) - In the early part of the COVID-19 pandemic, many areas of the country banned nonessential medical procedures in an effort to slow the spread of the disease. As a result, many physicians saw fewer patients for routine medical care, such as physical exams and screenings. A recent survey by The Physicians Foundation polled 3,513 physicians and found 41% saw volume decreases of 26% or more in their practices.
The impact on cancer screenings was even more profound. For example, screenings for prostate cancer — one of the most commonly diagnosed cancers in men in the United States — dropped by 56% by the peak of the pandemic in April according to a recent study published in JCO Clinical Cancer Informatics. The study used a large medical claims clearinghouse database representing 5-7% of the Medicare fee-for-service population to characterize changes in the utilization of cancer care services and gain insight into the impact of COVID-19 on the U.S. cancer population.,
“Last year, we saw many patients deciding to either reschedule or completely forgo preventative care in our office to avoid the risk of COVID-19 infection,” said Neal Shore, M.D., F.A.C.S., Medical Director, Carolina Urologic Research Center. “There was also a noticeable decline in the number of prostate cancer screens we conducted which, as a physician treating men with this cancer on a daily basis, makes me concerned that prostate cancer may not be detected in its earlier stages when outcomes are typically better for the patient.”
In the case of localized prostate cancer, the five-year relative survival rate is estimated to be 100 percent after diagnosis, according to the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program (SEER) database. For advanced prostate cancer types, such as metastatic castration-sensitive prostate cancer (mCSPC), which is prostate cancer that has spread to other parts of the body and responds to treatment to lower testosterone or castration-resistant prostate cancer (CRPC), which is prostate cancer that no longer responds to treatment to lower testosterone, the outlook is not as good. According to the same SEER analysis, only about 30 percent of men diagnosed with mCSPC will survive five years post-diagnosis and other studies have shown that men with CRPC have a median survival of between 9 and 30 months., This contrast in survival outcomes highlights why early prostate cancer detection is so critical.
In advanced prostate cancer treatment, a goal is to slow the spread of cancer cells in the body. All men have hormones known as androgens (the most common androgen is testosterone), which can fuel prostate cancer growth. For those with metastatic CSPC and CRPC, physicians may prescribe a treatment called a novel hormone therapy. These therapies interfere with the connection between androgens and androgen receptors. This can help slow cancer cell spread. Novel hormone therapies are paired with another treatment called androgen deprivation therapy (ADT) which reduces the total amount of testosterone in the body. Together, these therapies work to slow the spread of prostate cancer.
XTANDI® (enzalutamide), a prescription treatment approved by U.S. Food and Drug Administration (FDA), is an example of one of these novel hormone therapies, and is just one potential treatment option that patients can discuss with their doctors. XTANDI is FDA-approved to treat three forms of advanced prostate cancer: mCSPC (prostate cancer that has spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower testosterone), nmCRPC (prostate cancer that has not spread to other parts of the body and no longer responds to a hormone therapy or surgical treatment to lower testosterone) and mCRPC (prostate cancer that has spread to other parts of the body and no longer responds to a hormone therapy or surgical treatment to lower testosterone). XTANDI may cause serious side effects, including seizure, a condition involving the brain called Posterior Reversible Encephalopathy Syndrome (PRES), allergic reactions, heart disease, and falls and fractures, and more. See Important Safety Information below, and talk to your doctor or pharmacist.
“While my goal is to detect prostate cancer as early as possible, this does not always happen, particularly with ongoing concerns around COVID-19 delaying periodic check-ups,” continued Dr. Shore. “When a man does present with or progress to mCSPC or CRPC, there are treatment options like XTANDI they can discuss with their healthcare providers.”
While COVID-19 continues to be a concern for many men across the country, organizations like the American Cancer Society recommend talking to your provider who can discuss whether screening is recommended and help balance the risk and benefits of being screened now or postponing. To learn more about prostate cancer and XTANDI, visit https://www.xtandi.com/.
What is XTANDI?
XTANDI is a prescription medicine used to treat men with prostate cancer that:
It is not known if XTANDI is safe and effective in females or children.
Important Safety Information
What should I tell my doctor before taking XTANDI?
Tell your doctor about all your medical conditions, including if you:
How should I take XTANDI?
What are the possible side effects of XTANDI?
XTANDI may cause serious side effects including:
Your doctor will stop treatment with XTANDI if you have serious side effects.
The most common side effects of XTANDI include:
XTANDI may cause fertility problems in males, which may affect the ability to father children. Talk to your doctor if you have concerns about fertility.
These are not all the possible side effects of XTANDI. For more information, talk to your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
For further information, please talk to your doctor and click here to see Patient Information and Full Prescribing Information for XTANDI.
This article is sponsored by Astellas.
 The Physicians Foundation. 2020 Survey of America’s Physicians. https://physiciansfoundation.org/research-insights/2020physiciansurvey/ Accessed 01-04-2021.
 Patt D, Gordan L, Diaz M, et al: The Impact of COVID-19 on cancer care: How the pandemic is delaying cancer diagnosis and treatment for American seniors. JCO Clin Cancer Inform 2020;4:1059-71.
 National Cancer Institute. Cancer stat facts: prostate cancer. https://seer.cancer.gov/statfacts/html/prost.html. Accessed 05-04-2020 .
 Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65(11):1180-92. doi: 10.1111/j.1742-1241.2011.02799.x. PMID: 21995694.
 American Society of Clinical Oncology. ASCO Answers: Prostate Cancer (2018). http://www.cancer.net/sites/cancer.net/files/asco_answers_guide_prostate.pdf. Accessed 09-02-2020.
Other items that may interest you
We have noticed you are using an ad blocking plugin in your browser.
The revenue we receive from our advertisers helps make this site possible. We request you whitelist our site.